Status:
COMPLETED
A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
Brief Summary
This study is designed to compare the pharmacokinetics of three different formulations of Pf-04937319
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG or clinical laboratory tests.
- Subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28-days after the last dose of treatment.
- Body Mass Index (BMI) of 23 to 33 kg/m2 and a total body weight \>=50 kg (110 lbs).
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (excluding untreated seasonal allergies).
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- A positive urine drug screen.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01513928
Start Date
January 1 2012
End Date
February 1 2012
Last Update
March 12 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Singapore, Singapore, Singapore, 188770